{"product_id":"organon-business-model-canvas","title":"Organon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: Strategic blueprint to drive value, capture market share, boost growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Organon’s business model: this in-depth Business Model Canvas reveals how the company drives value, captures market share, and maintains competitive advantage. Ideal for entrepreneurs, consultants, and investors seeking actionable insights. The downloadable Word and Excel files provide a section-by-section breakdown for benchmarking and strategy. Purchase now to accelerate your analysis and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and academic research partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with CROs and academic research centers accelerates cost‑efficient clinical development across women’s health and biosimilars, leveraging scalable trial operations and expertise while the FDA had approved about 40 biosimilars by 2024. These partners provide access to specialized trial sites and curated patient cohorts, tapping into registries and ClinicalTrials.gov which lists over 460,000 studies. They complement internal R\u0026amp;D with cutting‑edge science and generate peer‑reviewed outcomes that strengthen credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMOs and API suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with CDMOs and API suppliers supports scalable, quality‑assured manufacturing of complex biologics and small molecules while lowering Organon’s capex and preserving flexible capacity. The global CDMO market grew at about an 8% CAGR to 2024, underscoring industry capacity expansion and rapid tech‑transfer capabilities for new launches. These partners ensure GMP compliance and cross‑region supply continuity, reducing launch and lifecycle risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, wholesalers, and pharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDistributors, wholesalers and pharmacy networks extend Organons reach across 140+ markets and partner with the three major US wholesalers that supply over 90% of hospitals, enabling last‑mile delivery to hospitals and retail pharmacies. They raise service levels and inventory turns, bolster cold‑chain integrity to limit spoilage, feed demand intelligence on prescribing and seasonal patterns, and support access programs in emerging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs, and government health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon negotiates formulary access, reimbursement and tender awards with payers, PBMs and government health systems to secure market entry and multi‑year volume stability; global pharmaceutical sales reached $1.6 trillion in 2024 (IQVIA). It aligns on value evidence, real‑world outcomes and budget impact to drive coverage decisions. Co‑creates affordability schemes for women’s health to expand access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNegotiate formulary, reimbursement, tenders\u003c\/li\u003e\n\u003cli\u003eAlign on RWE and budget impact\u003c\/li\u003e\n\u003cli\u003eCo‑create affordability schemes for women’s health\u003c\/li\u003e\n\u003cli\u003eStabilize volume via multi‑year agreements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and NGO organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy and NGO partners inform unmet needs and shape patient‑centric solutions, improving education, adherence and screening in women’s health; WHO notes about 90% of cervical cancer deaths occur in low‑ and middle‑income countries, highlighting screening gaps where joint access initiatives are critical. Partnerships build trust and social impact credentials globally while expanding reach in low‑resource settings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInform unmet needs\u003c\/li\u003e\n\u003cli\u003eBoost education \u0026amp; adherence\u003c\/li\u003e\n\u003cli\u003eScale screening in low‑resource areas\u003c\/li\u003e\n\u003cli\u003eStrengthen trust \u0026amp; social impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeverage \u003cstrong\u003e460,000\u003c\/strong\u003e trials, \u003cstrong\u003e8%\u003c\/strong\u003e CDMO CAGR to scale to 140+ markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartner with CROs\/academia to cut clinical timelines and leverage about 460,000 ClinicalTrials.gov studies; FDA approved ~40 biosimilars by 2024. CDMO\/API partnerships support scalable GMP manufacturing amid an ~8% CDMO market CAGR to 2024. Payers, distributors and NGOs secure access across 140+ markets and target LMIC screening gaps where ~90% of cervical cancer deaths occur.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/academia\u003c\/td\u003e\n\u003ctd\u003e~460,000 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\/API\u003c\/td\u003e\n\u003ctd\u003e~8% CAGR to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/distributors\u003c\/td\u003e\n\u003ctd\u003e140+ markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGOs\u003c\/td\u003e\n\u003ctd\u003e~90% cervical deaths in LMICs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas tailored to Organon’s strategy, organized into the 9 classic BMC blocks with full narrative, insights, and competitive advantage analysis. Ideal for presentations, investor or bank discussions, it includes SWOT-linked evaluations and supports validation of product and market decisions using real company data in a clean, polished format.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Organon's business model with editable cells, relieving the pain of manual structure by saving hours on formatting while enabling quick team collaboration, board-ready summaries, and fast comparison across models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic R\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvance pipelines across contraception, fertility, menopause and related conditions through discovery and IND-enabling work, running Phase I–IV trials and observational studies across global sites. In 2024 Organon continued to prioritize R\u0026amp;D investment to support differentiated clinical and health-economic evidence generation and payer dossiers. All studies adhere to rigorous ethics and regulatory compliance and GCP standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecure approvals, manage variations, and maintain licenses across 140+ countries (Organon global footprint, 2024) while balancing regional regulatory requirements. Operate a robust QMS and cGMP batch-release processes to ensure product quality and continuity. Continuously monitor safety signals, execute risk-management plans, and maintain inspection readiness across sites and partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply chain orchestration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlan, produce, and distribute biologics and small molecules at scale, balancing internal and external CDMOs to hit throughput targets and revenue goals. Optimize cost, yield, and reliability across sites, targeting \u0026gt;95% OEE and continuous margin improvements. Manage cold chain, serialization, and inventory—global cold chain market ~220 billion USD in 2024—while executing business continuity and dual sourcing to mitigate supply disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and medical affairs engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDevelop comprehensive value dossiers, HEOR and pricing models to secure reimbursement and formulary placement; RWE\/HEOR influenced ~75% of payer decisions in 2024. Educate HCPs with clinical and real‑world evidence to drive guideline inclusion and KOL advocacy. Deploy patient support programs to improve adherence 10–30% and reduce total care costs 5–15% (2024 meta‑analyses).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue dossiers: HEOR-driven pricing\u003c\/li\u003e\n\u003cli\u003eHCP education: RWD + clinical evidence\u003c\/li\u003e\n\u003cli\u003eGuideline\/KOL: inclusion advocacy\u003c\/li\u003e\n\u003cli\u003ePatient programs: adherence 10–30% gain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio and lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePortfolio and lifecycle management focuses on extending assets via new indications, formulations, and geographies while defending brands after loss of exclusivity through differentiation and reliable supply; it emphasizes prioritizing high‑need women’s health segments and rebalancing the mix between established brands and biosimilars.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtend assets: indications, formulations, geographies\u003c\/li\u003e\n\u003cli\u003eDefend post‑LOE: differentiation, supply reliability\u003c\/li\u003e\n\u003cli\u003ePrioritize women’s health highest unmet need\u003c\/li\u003e\n\u003cli\u003eRebalance portfolio: legacy brands vs biosimilars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing contraception, fertility \u0026amp; menopause: global approvals, CDMO scale and HEOR-driven access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvance pipelines in contraception, fertility and menopause via discovery, IND enabling and Phase I–IV trials; Organon prioritized R\u0026amp;D in 2024 to support differentiated clinical and HEOR evidence. Maintain approvals across 140+ countries, cGMP\/QMS and safety monitoring. Scale production with CDMOs targeting \u0026gt;95% OEE and dual sourcing. Use HEOR\/RWE (~75% payer influence in 2024) and patient programs to drive reimbursement and adherence gains.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Organon Business Model Canvas—not a mockup or sample—and shows the same content and layout you’ll receive after purchase. When you complete your order, you’ll instantly download this exact file, fully formatted and ready to edit and present. No surprises, just the real deliverable in its complete form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162210185593,"sku":"organon-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/organon-business-model-canvas.png?v=1762697382","url":"https:\/\/portersfiveforce.com\/products\/organon-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}